Stockscreener 앱 받기
6.94
0.72%
-0.05
시간 외 거래:
6.95
0.010
+0.14%
Evolus Inc 주식(EOLS)의 최신 뉴스
(EOLS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
EOLSEvolus Inc Options - Finviz
Evolus (EOLS) price target decreased by 11.11% to 14.96 - MSN
Evolus Q1 2026 earnings preview - MSN
Price to sales forward of Evolus, Inc. Common Stock – NASDAQ:EOLS - TradingView
Enterprise value to EBITDA forward of Evolus, Inc. Common Stock – NASDAQ:EOLS - TradingView
Enterprise value to revenue forward of Evolus, Inc. Common Stock – NASDAQ:EOLS - TradingView
Evolus, Inc. Actuals & Estimates (NASDAQ:EOLS) - TradingView
EVL Forecast — Price Target — Prediction for 2027 - TradingView
EOLS Forecast — Price Target — Prediction for 2027 - TradingView
EOLS News | EVOLUS INC (NASDAQ:EOLS) - ChartMill
Evolus Inc (EOLS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Evolus, Inc.(NasdaqGM: EOLS) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
Is Evolus (EOLS) Finally Turning the Corner on Profitability - Kavout | AI
Evolus Inc (EOLS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Evolus Inc (EOLS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Evolus Inc (EOLS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Evolus Inc (EOLS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Evolus Inc (EOLS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Evolus Inc (EOLS) Institutional Confidence - TradingKey
Evolus Inc (EOLS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Evolus Inc (EOLS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BTIG Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $13 - Moomoo
EOLS Reiterated by BTIG -- Price Target Maintained at $13.00 - GuruFocus
[EFFECT] Evolus, Inc. SEC Filing - Stock Titan
Understanding the Setup: (EOLS) and Scalable Risk - Stock Traders Daily
Evolus shareholders re-elect directors and approve executive compensation By Investing.com - Investing.com South Africa
Evolus shareholders re-elect directors and approve executive compensation - Investing.com
Evolus (EOLS) shareholders approve directors, auditor and say-on-pay at 2026 meeting - Stock Titan
Evolus, Inc. (EOLS) reports Q1 loss, tops revenue estimates - MSN
Mizuho Securities Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Evolus (NASDAQ: EOLS) registers $250M shelf; $195.5M unsold re‑registered - Stock Titan
EOLS: Virtual Meeting with Management Scheduled on June 11 - GuruFocus
AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society - GlobeNewswire Inc.
Evolus (EOLS) Jefferies Global Healthcare Conference 2026 Summary - Quartr
The Technical Signals Behind (EOLS) That Institutions Follow - Stock Traders Daily
Evolus (EOLS) Q2 2025 Earnings Call Transcript - AOL.com
Evolus Shareholder Notice - TMX Newsfile
Evolus Update - TMX Newsfile
Evolus Class Action Reminder - TMX Newsfile
Evolus Shareholder Alert - TMX Newsfile
Earnings call transcript: Evolus Inc Q1 2026 misses EPS forecast, stock rises - Investing.com Nigeria
Precision Trading with Evolus Inc. (EOLS) Risk Zones - Stock Traders Daily
Evolus to Participate in The Jefferies Global Healthcare Conference - Business Wire
Evolus To Roll Out Estyme Injectable Hyaluronic Acid Fillers in Europe - The Dermatology Digest
TradingKey - TradingKey
Evolus Completes Key NUCEIVA Safety Study, Easing Risk for Aesthetic Toxin Investors - TipRanks
Evolus (EOLS) to Launch Estyme Injectable Collection in Europe - GuruFocus
Evolus to launch Estyme dermal filler line in Europe on May 16 - Investing.com UK
Evolus to Launch Estyme Dermal Fillers in Europe - Orange County Business Journal
Evolus to launch Estyme dermal filler line in Europe on May 16 By Investing.com - Investing.com South Africa
Evolus, Inc. Launches Estyme Injectable Hyaluronic Acid Gels Collection in Europe - marketscreener.com
0.15%
1.95%
자본화:
|
볼륨(24시간):